May 22, 2023 11:05 AM EDTUpdated 02:50 PM
R&D

Rain On­col­o­gy's stock dives af­ter tu­mor treat­ment fails a PhI­II tri­al

Tyler Patchen

News Reporter

Rain On­col­o­gy’s treat­ment for ded­if­fer­en­ti­at­ed li­posar­co­ma failed a Phase III clin­i­cal tri­al, rais­ing ques­tions about what’s next for the Bay Area biotech’s lead can­di­date. …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Jazz wins ap­proval for bis­pe­cif­ic in bil­iary tract can­cer

RFK Jr. and Elon Musk want to ban phar­ma ads. They would­n't be the first to try

FDA ad­comm rais­es risk ques­tions on As­traZeneca’s An­dexxa

No­var­tis seeks more bolt-on deals as it pur­chas­es neu­ro start­up for up to $1.1B

At Jef­feries, all that man­u­fac­tur­ers want to talk about is GLP-1s

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times